Free shipping on all orders over $ 500


Cat. No. M1940
Docetaxel Structure

Taxotere; RP-56976

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
25mg USD 36  USD36 In stock
50mg USD 56  USD56 In stock
100mg USD 86  USD86 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Docetaxel is a clinically well-established anti-mitotic chemotherapy medication. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules. It has also been found to lead to the phosphorylation of oncoprotein bcl-2, which is apoptosis-blocking in its oncoprotein form. Docetaxel exhibits cytotoxic activity on breast, colorectal, lung, ovarian, gastric, renal and prostate cancer cells. Docetaxel does not block disassembly of interphase microtubules and so does not prevent entry into the mitotic cycle, but does block mitosis by inhibiting mitotic spindle assembly. Docetaxel activity is significantly greater in ovarian and breast tumours than for lung tumours. Docetaxel prevents microtubule depolymerization and disassembly in the absence of GTP.

Product Citations
Customer Product Validations & Biological Datas
Source Mol Med Rep 2020 Nov. Figure 2. docetaxel (Abmole Bioscience Inc, Houston, TX, USA)
Method Determination of A549/DTX cells
Cell Lines A549/DTX cells
Concentrations 0, 2.5, 5, 10 or 20 µM
Incubation Time 24 h
Results Docetaxel treatment increased the protein expression levels of LC3A, Beclin-1, p‑AKT and PARP in A549/DTX cells compared with the control
Protocol (for reference only)
Cell Experiment
Cell lines A549, HCT-116, NCI-H838, KB-3-1, MX-1W, NCI-H1299 and DLD-1 cells
Preparation method Cell Proliferation Assays
Cytotoxicity was assessed by growing cells in the presence of agents for 72 h. Cell survival was measured by the sulforhodamine B (SRB) protein stain method or the ATP-binding assay using the Cell-Titer Glo Luminescent Reporter (GLR) System (Promega, Inc., Madison, WI). The SRB assay was done as previously described (23). For the GLR system, cells were plated robotically at approximately 50% confluency in a 384-well plate and allowed to attach for 12 h at 37°C/5% CO2. After diluting test agents using BioMek 2000 robotic system (Beckman Instruments, Fullerton, CA), agents were added to each well and incubated for 72 h. ATP binding and stabilization of the luminescent signal were performed according to manufacturer's protocol (Promega) following tumor cell lysis. Absorbance was read on a Victor V multilabel plate reader (Perkin-Elmer, Gaithersburg, MD) at a wavelength of A595 and data collected using Wallac 1420 Workstation software.
Concentrations 0~100 nM
Incubation time 72 h
Animal Experiment
Animal models Athymic nu/nu female mice bearing Lox melanoma cells, KB-3-1 cells and A375SM melanoma cells tumour xenograft model
Formulation 1.4% ethanol/3.5% polysorbate 80 in saline
Dosages 25 mg/kg
Administration i.v.
Chemical Information
Molecular Weight 807.88
Formula C43H53NO14
CAS Number 114977-28-5
Solubility (25°C) DMSO 60 mg/mL
Ethanol 60 mg/mL
Storage 2-8°C, protect from light, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Chenrui Li, et al. J Pharm Biomed Anal. Non-linear pharmacokinetics of piperine and its herb-drug interactions with docetaxel in Sprague-Dawley rats

[2] Domingo-Domenech J, et al. Cancer Cell. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.

[3] Lyseng-Williamson KA, et al. Drugs. Docetaxel: a review of its use in metastatic breast cancer.

[4] Sampath D, et al. Mol Cancer Ther. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.

Related Microtubule Products
P34cdc2 Kinase Fragment

P34cdc2 Kinase Fragment is associated with the completion of DNA replication in yeast mitosis.


Cemadotin (LU103793) is an analogue of Dolastatin 15 which is naturally occurring cytotoxic peptides.


VLS-1488 is an orally active KIF18A inhibitor that inhibits KIF18A microtubule-dependent ATPase activity with an IC50 value of 0.016 μM.


ENMD-1198 (IRC-110160), an orally active microtubule destabilizing agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity.


Tubulin/JAK2-IN-1 is a dual inhibitor of Janus kinase 2 (JAK2) and microtubule.

Abmole Inhibitor Catalog

Keywords: Docetaxel, Taxotere; RP-56976 supplier, Microtubule, inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.